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Introduction 
This report presents statistics on drug utilization 
during office visits to general and family practitioners, 
internists, pedlaticians, and obstetrician-gynecologists, 
i@e physicians generally acknowledged to be most 
~,wolved in the delivery of primary health care. The 
data were gathered in 1980 by the National Center for 
Health Statistics by means of the National Ambulatory 
Medical Care Survey. 
For purposes of health manpower legislation (PL 94-
484, 1976), Congress identitled general and family 
practitioners, internists, and pediatricians as primary 
care providers. However, it is the policy of the American 
Medical Association to include obstetrician-gynecolo-
gists in the group of primary care providers. A 1978 
Institute of Medicine study defined primary health care 
in terms of the scope, character, and integration of the 
services provided.1 The report indicated that although 
primary care may be provided by many types of health 
professionals and by physicians in many diflierent 
specialties, the physicians whose practice content fit 
the dimensions of primary care most closely were 
general and family practitioners, internists, pediatri-
cians, and obstetrician-gynecologists. The National Am-
bulatory Medical Care Survey was the principal source 
of data used by the Institute of Medicine to describe the 
content of primary health care. 
The National Ambulatory Medical Care Survey is 
a probability sample survey conducted annually through 
.1981 by the Division of Health Care Statistics of the 
National Center for Health Statistics. The technical 
iotes at the end of this report provide brief ini30nnat.ion 
about the source of the data, sampling errors, and 
deftitions of terms. A complete description of the sur-
vey including limitations and definitions was published 
in Vital and Health Statistics, Series 13, No. 66.2 The 
methodology used to collect and process the drug infor-
mation is described in Vital and Health Statistics, 
Series 2, No. 90.3 
The Patient Record form used in the 1980 survey is 
reproduced in figure 1. Up to eight specific drugs, either 
new or continued during the visit, maybe recorded by the 
physician in item 11, parts a and b. In order to present 
accurately what the physician ordered, prescribed, or 
provided, drug mentions used in this report are based on 
the physicians’ entries on the Patient Record forms. 
These entries were brand or generic names of prescription 
(~) or nonprescription (over-the-counter) drugs, and in 
some irstances the physician recorded a therapeutic 
effect; e.g., “allergy relief.” 
Data highlights 
Visit characteristics . 
Primary care physicians constituted 54 percent of the 
NAMCS physician universe, but had 66 percent of the 
office visits and accounted for 74 percent of all drug men-
tions (table 1). Among this group of physicians, general 
and family practitioners (GFP’s) had a disproportionately 
large share of visits and drug mentions. They had 33 per-
cent of the visits and 41 percent of the drug mentions 
although they represented only 23 percent of the physician 
universe. Obstetrician-gynecologists (OBG’S) accounted 
for only 5 percent of the drug mentions compared with 10 
percent of the visits, mainly because a relatively large 
proportion of their visits involve prenatal and postpartum 
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Figure 1. Patient Record from the Netional Ambulato~ Medical Care Survey 
care, and examinations for which drugs are generally not 
indicated. 
The patterns of medication therapy presented in this 
report differ by specialty because drug utilization is 
highly related tQ the patient’s age, sex, and condition. 
Although GFP’s, internists, pediatricians, and OBG’S 
provide primary care, their patients have different demo-
graphic characteristics and present more, or less, of cer-
tain diagnoses. Patterns of medical care thus vary depend-
ing on the case-mix. Table 2 shows the distribution of 
office visits to primary care physicians by age and sex of 
the patient. By age group, GFP’s see a more heterogen-
eous group of patients than do the other physicians. 
Internists provide care chiefly to adults over 24 years of 
age, and to a larger proportion of patients over 44 years of 
age (69 percent) than do GFP’s (44 percent). Pediatri-
cians chiefly treat children under 15 years of age. Visits 
by women in the child-bearing years, 15–44, account for 
87 percent of the OBG’S caseload. Because medication 
therapy, diagnosis, and the patient’s age and sex are 
highly intercorrelated, the range of drug utilization a 
the classes of drugs prescribed vary among speciali.
T 
OffIce visits and drug mentions 
The number of ofllce visits, the number and percent 
of visits in which one or more drugs were prescribed (drug 
dmcd#fi3 
visits), and the number of drug mentions are shown in 
T 
r 
.@ble 3. The drug mention rate is the number of drug men-
ons divided by the number of visits; e.g., GFP’s re-
.orded an estimated 279,186,000 drug names on 
Patient Record forms during 191,744,000 visits, which 
results in a drug mention rate (DMR), or average over 
all visits, of 1.46 drugs per visit. Another approach to 
measuring drug use is to divide the number of drug men-
tions by the number of drug visits (a visit in which one 
or more drugs were ordered). Thus, when drugs were 
prescribed, the average number a patient received (drug 
intensity rate, DIR) when visiting a GFP was 1.93. The 
percent of drug visits and the DIR are used in this report 
to make comparisons among specialties. 
Proportions of total visits with one or more drugs 
prescribed were similar for GFP’s (75 percent), inter-
nists(76 percent), and pediatricians (71 percent). Only 
44 percent of OBG’S visits included any drugs, reflect-
ing the large volume of visits for routine prenatal care 
and gynecological examinations. However, the frequency 
of drug visits varies by age of the patient. The rising 
proportions of drug visits after age group 15–24 years 
for GFP’s and internists is shown in figure 2, in which 
there is a striking similarity in the configuration of the 
two curves. 
In figure 3 proportions of drug visits to GFP’s are 
compared with those to pediatricians. Children under 
1 years of age who visited GFP’s were more likely to 
e given at least one medication than were their counter-
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Figure 2. Percent of drug viaita by age of patient and selected primary care 
physician specialty United States, 1980, 
pronounced for the age group 3–5 years. Although the 
GFP routinely treats children in the same age range as 
those of the pediatrician, visits to the pediatric special-
ist are more likely to be for routine examinations where 
medication therapy is not always indicated. Two pre-
ventive health care diagnoses, health supervision of 
infant or child and general medical examination, ac-
counted for 27 percent of visits to pediatricians by 
25 and 
f- Under 3 3-5 6-10 11–14 15-24 25-44 45–64 65 
and 
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1 Age in years 
Figure 3, Percent of drug visits by age of patient and selected primary care physician special~ United States, 1980 
I 
4 
children under 11 years of age compared with only 16 
percent of those to GFP’s. 
An even more marked difference is evident in fig-
ure 4 in which proportions of drug visits by the age 
group of women visiting GFP’s and OBG’S are plotted. 
Percents are consistently higher for GFP’s than for 
OBG’S. The curves exhibit a similar pattern of change 
except that women’s drug visits to GFP’s decline until 
age group 15–24 years while the low point of drug visits 
to OBG’S is at age group 25–44 years. The lower pro-
portions of drug visits found in the OBG’S practice is 
explained by the preponderance of visits with diagnoses 
of normal pregnant y, postpartum care, and gynecologi-
cal examinations (a total of 48 percent of all visits). 
Only 7 percent of women’s visits to GFP’s were repre-
sented by these diagnoses. 
On the average, the highest number of drugs 
prescribed during drug visits was by internists, with a 
rate of 2.24 drugs per drug visit, followed by GFP’s 
with 1.93 (table 3). These rates are plotted by patient 
age group in figures 5–7. Figure 5 illustrates drug inten-
sity rates for GFP’s and internists. As expected, rates 
increase with increasing age after age group 15–24 
years, regardless of which of the two specialists was 
visited. At that point, however, the curves diverge, and 
beginning with age group 25–44 years, internists pre-
scribed higher numbers of medications than GFP’s did. 
90 r 
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physician specialty: United States, 1980 
Differential diagnosis is likely to contribute to this dif-
ference in rates. 
Although it was shown in figure 3 that a higher per-
cent of visits by children under 11 years of age to GFP’s 
included one or more drugs than did those to pediatri-
cians, figure 6 shows that when drugs were used, the 
average numbers prescribed by both types of physicians 
were very close. 
For every age group shown in figure 7, GFP’s pre-
scribed a higher average number of drugs than OBG’S 
did, and the number prescribed tended to increase with 
increasing age group after 15–24 years for GFP’s and 
after 25–44 years for OBG’S. The data illustrated in 
figures 4 and 7 reveal that not only did GFP’s have 
more drug visits, but they also prescribed more drugs 
during those visits than OBG’S did. However, these 
findings are clearly related to the lower proportion of 
illness-related visits made to OBG’S, as noted previously. 
Number of medications 
The proportions of visits that included precisel, 
one, two, three, or four or more drugs are listed .in tabler 
4. In the first part of this table distributions are based on 
all visits and thus they include a “none” category. In the 
lower section, distributions are based on the number of 
&ncedata 5 
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Figure 6. Drug intensity rate by age of patient and selected primary care physician specialty United States, 1980 
o 
drug visits and, therefore, arrays do not include the 
“no-ne” category. The proportio-ns in this category are 
simply the complements of the percents of drug visits 
shown in table 3. For patients treated by GFP’s, intern-
ists, and pediatricians, the largest proportions of visits 
were in the category of one drug mention, but the 
majority of visits to OBG’S had no drugs mentioned. 
When OBG’S did order drugs, 72 percent of visits 
included only one. Internista were more likely than 
other primary care physicians to order three or more 
drugs. About 34 percent of their drug visits included 
this number compared with 24 percent of GFP’s, 13 
percent of pediatricians, and 7 percent of OBGS. This 
was not unexpected in view of their relatively high pro-
portion of visits by the elderly. It has been shown that, 
in general, and for certain diagnoses, the number of 
drugs ordered increases as the patient’s age group 
increases.1-6 
Drug status characteristics 
NAMCS drug data are characterized by entry 
status (brand name,a generic entity, or therapeutic ef-
fect), prescription status (prescription or over-tlie-
counter drug), and composition status (single ingredient, 
combination drug, or multivitamin). Drug mentions are 
distributed by these variables in table 5. The most com-
mon method employed by physicians to enter drugs on 
aInclusion of brand or trade names is for identification only and does not im-
ply endorsement by the Pablic Health Service or the U.S. Department of 
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the Patient Record form was by brand name. GFP’s, 
internists, and OBG’S used brand names (manufacturer’s 
product name) in over 70 percent of mentions; pediatri-
cians in about 58 percent. Pediatricians are more likely 
than other specialists to enter drugs by generic name 
because of their frequent use of immunizing agents and 
other injectable drugs. Prescription drugs were also 
more frequently ordered than over-the-counter drugs, 
ranging from 76 percent of mentions by OBG’S to 85 
percent of those by internists. Drugs consisting of a 
single principal ingredient were more likely to be 
prescribed than combination drugs byintemists, GFP’s, 
pediatricians, and OBG’S, in declining order of fre-
quency. 
The NAMCS file also includes information on the 
Federal control status of each drug utilized. Drugs 
under the regulatory control of the Drug Enforcement 
Administration of the U.S. Department of Justice are 
assigned by them to one of five schedules based on 
potential for abuse and psychological or physical 
dependence, ranging from schedule I with the highest 
potential for abuse and dependence to schedule V with 
the lowest (see reference 3 for a more detailed explana-
tion of the schedules and examples). Drug mentions are 
classfled in table 5 according to whether they are con-
trolled or uncontrolled drugs. A very small proportion 
of drugs listed by primary care physicians were feder-
ally controlled, amounting to 11 percent of all mentions 
by GFP’s, 8 percent by internists, and 5 percent each o { 
those by pediatricians and OBG’S. For GFP’s, intern ‘ 
mists, and OBG’S, the majority of controlled drugs were 
in schedule IV (53, 58, and 62 percent, respectively). 
For pediatricians, 62 percent of controlled drugs men-
tioned were in schedule V. 
Therapeutic categories 
Each specific drug mentioned in NAMCS is a 
member of a group of drugs identiiled by the desired 
therapeutic effect. These groups are based on the classi-
fication system of the American Hospital Formulary 
Service.T Drug mentions are aggregated by therapeutic 
categories in table 6. The leading category of drugs used 
varied among the primary care physicians, reflecting the 
demographic and clinical characteristics oftheirpatients. ~ 
For GFP’s, central nervous system drugs accounted for 
the largest share of their mentions ( 19 percent). Inter- 
nistsused cardiovascular drugs (21 percent) proportion- 
ately more often than other drugs. Pediatricians most 
often used anti-infective agents (29 percent). Hormones 
and synthetic substitutes constituted the major portion 
of mentions by OBG’S (26 percent). 
The five leading categories prescribed by both 
GFP’s and internists, although in different order of 
frequency, were anti-infective agents; cardiovascular 
drugs; central nervous system drugs; electrolytic, caloric, o 
and water balance; and hormones and synthetic substi-
tutes. These five categories accounted for 62 percent of 
drug utilization by GFP’s and 70 percent of that by 
internists. Three of these classes were also among the t 
five most frequently used by OBG’S: anti-infective 
agents, central nervous system drugs, and hormones 
and synthetic substitutes. Two other categories fre-
quently ordered by OBG’S were skin and mucous mem-
brane preparations (10 percent) and vitamins (19 per-
cent). Pediatricians prescribed antihistamine drugs; 
expectorants and cough preparations; and serums, 
toxoids and vaccines proportionately more frequently 
than did the other primary care physicians. 
Specific drug mentions 
Because GFP’s see a large number of patients in 
every age group ranging from infants to the elderly, the 
number and percent of the most frequently ordered 
specific drugs are ranked by age group in table 7. The 
other primary care specialties have a more homogeneous 
patient load. Therefore, specific drugs are listed but not 
shown by age group, for internists (chiefly adults) in 
table 8, for pediatricians (chiefly children) in table 9, 
and for OBG’S (chiefly women 15–44 years of age) in 
table 10. The reader is cautioned that estimates may l 
not differ from other near estimates due to sampling 
variability. Therefore, ranks may be somewhat artificial. 




tion therapy, GFP’s prescribed Ampicillin, Amoxicillin, 
and Penicillin in a total of 11 percent of drug mentions. 
imetapp was the leading antihistamine ordered (4 
ercent). Diphtheria and tetanus toxoids and pertussis 
vaccine (DPT), and poliomyelitis vaccine each ac-
counted for 4 percent of mentions. Aspirin was men-
tioned in 3 percent. 
Penicillin and Ampicillin led the list of drugs 
mentioned when patients visiting GFP’s were 15–24 
years old or 25–44 years old. However, the variety of 
drugs ordered changed perceptibly beginning with age 
group 25-44 years. While 16 drugs accounted for 42 
percent of mentions for patients under 15 years, it took 
twice as many or more to account for about the same 
proportion of mentions for patients in the three older 
groups. The diuretic, Lasix, appears for the first time 
among the leading drugs ordered for patients 25–44 
years of age. Over 1 million mentions of chorionic 
gonadotropin, a hormone frequently associated with a 
diagnosis of obesity, also appear on the list for 25–44 
year old patients as well as three anorexients used in the 
treatment of obesity: Ionarnin, Fastin, and Phentermine 
(all three are the generic entity phentermine, making a 
total of 1.7 million mentions of this substance). 
An increase in the number of different diuretics 
utilized in treating patients 45–64 years old reflects the 
increase of cardiovascular problems. Dyazide, Lasix, 
ydrodiuril, Hygroton, and Hydrochlorothiazide were 
ong the top 10 drugs ordered for this age group. 
Inderal, a drug often used to treat hypertension and cer-
tain heart conditions, was the second leading number of 
mentions. Inderal, as well as the previously mentioned 
diuretics were also among the most frequently men-
tioned drugs when patients were in the 65 years and 
over age group. Also frequently prescribed for this age 
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Table 1. Number and percent distribution of physicians in NAMCS physician universe and percent distribution of visits and drug mentions, by physician 
specialty United States, 1980 
I 
Physician specialty NAMCS physician universe Visits Drug 
PercentNumber Percent distributiondistribution 
Total physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227,558 100.0 100.0 100.0 
Total primary care physicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . .’. . . . . . . . 122,635 53.9 66.2 74.2 
General and family practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53,147 23.4 33.3 41.1 
internal medicine, ., ., .,...,.,. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35,199 15.5 12.1 17.5 
Pediatrics, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16,043 7.1 11.2 10.7 
Obstetrics and gynecology ..,...... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18,246 8.0 9.6 4.9 
Other specialties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104,923 46.1 33.8 25.8 
Table 2. Percent distribution of visits by age and sex of patient, according to primay care physician specialty United States, 1980 
Primary care physician 
Age and sex of patient 
General and Internal Obstetrics andPediatricsfamily practice medicine gynecology 
Percent distribution 
Alleges . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100.0 100.0 100.0 
Under 15 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.9 2.5 92.5 1.0 
16-24 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.9 7.1 5.9 32.0 
25-44 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27,4 21.4 1.0 55.1 l45–64 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24.4 36.4 “0.4 9.4 
65 years and over . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.4 32.7 “0.2 2.5 
Sex 
Female . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60.5 59.2 46.3 98.7 
Male . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39.5 40.8 53.7 1.3 
Table 3. Number of office visits, number and percent of drug visita, number of drug mentions, drug mention rate, and drug intensity rate per visit, 
by primary care physician special~: United States, 1980 












per drug visit7 
General and family practice ., 191,744 144,478 75.3 279,186 1.46 1.93 
Internal medicine........,.,., . . 69,481 53,091 76.4 118,943 1.71 2.24 
Pediatric . . . . . . . . . . . . . . . . . . . . . 64,223 45,575 71.0 72,825 1:13 1.60 
Obstetrics and gynecology. . . . 55,123 23,984 43.5 33,026 0.50 1.38 
1A visit in which one or more drugs were prescribed 
‘Drug mentions A number of visits. 
3Dr”g ~e”tio”~ + number of drug visits. 
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Table 4. Number and percent distribution of office visits by number of medications for all visita and for drug visits, according to primary care physician specialty 
United States, 1980 
T 
Primary care physician 







Number in thousands 
All visits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191,744 69,481 64,223 55,123 
Percent distribution 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100.0 100.0 100.0 
None . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24.7 23.6 29.0 56.5 
l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34.4 29.1 40.4 31.2 
2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23.0 21.4 21.6 9.3 
3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.5 13.0 6.4 2.3 
4 or more . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.6 13.1 2.5 0.8 
Number in thousands 
Drug visitsl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144,478 53,091 45,575 23,984 
Percent distribution 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100.0 100.0 100.0 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45.6 38.1 57.0 71.7 
; . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30.5 28.0 30.5 21.3 
3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.9 17.0 9.0 5.2 
4 or more . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.0 16.9 3.6 1.8 
1A “i~it in which one or more drugs were prescribed. 
P 
Table 5. Number and percent distribution of drug mentions by selected drug status characteristics, according to primary care physician special~ 
United States, 1980 
Primary care physician 
Drug status characteristic 
General and Internal Obstetrics andPediatrics
family practice medicine gynecology 
Number in thousands 
All drug mentions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279,186 118,943 72,825 33.026 
Percent distribution 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100.0 100.0 100.0 
Entry status 
Generic name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24.3 24.3 34.9 17.5 
Brand name . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71.2 72.8 57.8 77.8 
Therapeutic effect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 2.1 6.5 3.6 
Undetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.8 0.8 0.8 1.1 
Prescription status 
Prescription drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83.4 84.6 79.6 75.9 
Nonprescription drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12.0 12.5 13.1 19.4 
Undetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.6 2.9 7.3 4.8 
Composition status 
Single ingredient drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68.3 78.2 58.9 47.5 
Combination drug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25.3 18.1 32.5 32.6 
~ Multivitamin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.0 0.8 1.3 15.3 
Ph$fndetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.5 2.9 7.3 4.7 
Tyl 
Federal control status 
Controlled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.9 8.2 4.6 5.2 
Uncontrolled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84.5 88.9 88.0 90.0 
Undetermined . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.6 2.9 7.3 4.8 
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Table 6. Number and percent distribution of drug mentions by therapeutic catego~, according to primary cara physician specialty: Unitad Statea, 1980 
Primary care physician 
Therapeutic categoryl 
General and Internal Obstetrics an r 
Pediatrics 
family practice medicine gynecology 
All categories ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 279,186 118,943 72,825 33,026 
Percent distribution 
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100.0 100,0 100,0 100,0 
Antihistamine druga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,6 3.9 15.2 2.3 
Anti-infective agenda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16.2 6.9 28.8 16.9 
Antineoplastic agenda, .,.,..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
*O. 1 3.4 *o. 1 
Autonomic drugs,.,.,.,...,.,.,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ,,. 4.4 3.6 3.0 *1,5 
Blood formation and coagulation.,.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.4 1.5 “0.3 3.5 
Cardiovascular drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,.,.,,,. 9.9 20,7 “0.2 2.5 
Central newoussyatem drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18.5 18,2 4.8 8,0 
Diagnostic agents, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ,,, 0.3 “0.2 4.7 *O. 1 
Electrolytic, caloric, and water balance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ., 9,1 14.3 “0,3 3.1 
Expectorants and cough preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.3 1.9 6.8 “0.9 
Eye, ear, noaeand throat preparationa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.4 0.8 3.4 ‘0.5 
Gastrointestinal drugs, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ,., 4.6 4.7 1.6 *1.6 
Hormones and synthetic substitutes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.1 9,7 1,7 26.4 
Serums, toxoids and vaccines...,., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 0.9 17.8 “0.9 
Skin andmucoua membrane preparations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,9 2.4 5.9 9,9 
Spasmolytic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .,. 1.7 2.3 2.2 “0.5 
Vitamins, ., ., ., . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1 2.3 80,5 18.6 
Other, unclassified, orundetarmined. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.9 2.4 2.9 3.0 
18a~ed o“ the classification system of the American Hospital Formulaw Serwce (A. H. F.S.). See raference ~. 
dmcdata 11 
Table7. Number andpercent distribution ofdrugmentiona inoffice viaitsto general and family practitioners byageof patient andmostfrequently named drugs: 
United States, 1980 
.-. 
Number of Number of 
Age of patient mentions Percent Age of patient mentions Percent 
and name ofdrug~ in distribution and name of drugl in distribution 
thousands thousands 
Under 15 years . . . . . . . . . . . . . . . . . . . . . . 30,497 100.0 45–64 years. . ., .,, ,,, ,. . . . . . . 77,235 100,0 
Ampicillin . . . . . . . . . . . . . . . . . . . . 1,326 4.3 Dyezide . . . . . . . . . . . . . . . . . . . . . . 1,421 1.8 
Poliomyelitis vaccine..,.,.,.,.,,.. ., .,.,,,. 1,272 4.2 Indaral, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,324 .7 
Dimetapp . . . . . . . . . . . . . . . . . . . . . 1,225 4,0 Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,291 ,7 
Diphtheria and tetanus toxoids and Vitamin B–12 . . . . . . . . . . . . . . . . . . 1,287 ,7 
pertussis vaccine . . . . . .. . . . . . . . . 1,170 3.8 Motrin . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,125 .5 
Amoxicillin .,.,.,.....,.,,,,. . . . . . . . . . . 1,095 3.6 Hydrodiuril (hydrochlorothiazide) ., . . 1,026 .3 
Aspirin . . . . . . . . . . . . . . . . . . . . . . 995 3.3 Hygroton, . . . . . . . . . . . . . . . . . . . . . . . . . . 971 .3 
Penicillin. , .,,......,.,...,.. 963 3.2 Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . 960 .2 
Allergy relief or shots, . . . . . . . . . . . . . . . . 809 2.7 Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . 956 .2 
Reflex . . . . . . . . . . . . . . . . . . . . . . . 572 1.9 Hydrochlorothiazide . . . . . . . . . . . 953 1.2 
Erythromycin . . . . . . . . . . . . . . . . . . . . . . 548 1.8 Valium . . . . . . . . . . . . . . . . . . . . . . . 677 1.1 
Actifed . . . . . . . . . . . . . . . . . . . . . . . . . . 539 1.8 Tagamet . . . . . . . . . . . . . . . . . . . . . 867 1,1 
Arhoxil (amoxicillin) . . . . . . . . . . . . . 494 1.6 Thyroid . . . . . . . . . . . . . . . . . . . . . . . . . . 849 1.1 
E. E. S.(e~thromycin) . .,, ,, .,...... ,., .,,,,. 490 1.6 Tetracycline . . . . . . . . . . . . . . . . . . 759 1,0 
Benadryl . . . . . . . . . . . . . . . . . . . . . . . . . . . 484 1.6 Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 754 1.0 
Phenergan . . . . . . . . . . . . . . . . . . 456 1.5 Prednisone . . . . . . . . . . . . . . . . . . . . . . . . . . 732 0.9 
E-mycin (e~thromycin} . . . . . . . . . . . . . . 413 1.4 Diuril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 686 0.9 
Residual, . . . . . . . . . . . . . . . . . . . . 17,646 57.7 Lanoxin (digoxin) . . . . . . . . . . . . . . . 677 0.9 
Aldomet . . . . . . . . . . . . . . . . . . . . . 675 0.9 
15-24 years,.,.........,,,,.. 29,989 100.0 Indocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 633 0.8 
Penicillin, . . . . . . . . . . . . . . . . . . . . 
Ampicillin . . . . . . . . . . . . . . . . . . . . 




Lopressor . . . . . . . . . . . . . . . . . . . . 





Premarin . . . . . . . . . . . . . . . . . . . . 485 0.6Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 646 2,2 
Tetracycline . .,, . . . . . . . . . . . . . . 539 1,8 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . 477 0.6 
Tranxene, . . . . . . . . . . . . . . . . . . . . . . . 468 0.6 
Ilargyrelief or shots . . . . . . . . . . . . . . . . . 400 1.3 
Diabinese . . . . . . . . . . . . . . . . . . . 465 0.6 
nadryl ..,.......,.,,,,,.. *364 1.2 
8enadryl . . . . . . . . . . . . . . . . . . . . . . . . . . . . 454 0.6 
,energan expectorant with codeina 
’340 1.1 
Butazolidin Alka . . . . . . . . . . . . . . . . 453 0.6 
r {etanus toxoid .,, , .,.,..... . . . . . . . . . . . “340 1.1 Allergy relief or shots, . . . . . . . . . . . . . . . . . 
429 0.6 
Pramet FA. , .,.....,,,,,,,,,.. . . . . . . . . . *323 1.1 
Aidoril .,.,.,..............,., . . . . . . . . . 429 0.6 
Residual .,,,,,,,,.,.,....,,.. 23,665 79,6 
Phenobarbital . . . . . . . . . . . . . . . . . . . . . . . . . 





25–44 years.,..,,,........,,. 68,195 100,0 
Darvocet-N . . . . . . . . . . . . . . . . . . . . . . . . . . . 





Penicillin. . . . . . . . . . . . . . . . . . . . . 1,868 2.7 8rethine . . . . . . . . . . . . . . . . . . . . . . . . . . . . 406 0.5 
Ampicillin . . . . . . . . . . . . . . . . . . . . 1,395 2,0 Ser-ap-es . . . . . . . . . . . . . . . . . . . . . . . . . . 405 0.5 
Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,327 1.9 Erythromycin . . . . . . . . . . . . . . . . . . . . 402 0.5 
Tetracycline . . . . . . . . . . . . . . . . . . 1,216 .8 Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . 50,843 66.1 
Chorionic gonadotropin .,.,.... 1,095 .6 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,018 .5 
Vitamin B–l Z,.............,,.. 845 .2 
Allergy relief or shots, . . . . . . . . . 837 .2 65 years and over . . . . . . . . . . . . . . . . 
73,270 100.0 
Actifed, . . . . . . . . . . . . . . . . . . . . . . . . . 785 .2 Lanoxin (digoxin) . . . . . . . . . . . . . . . . . . . . 2,553 3.5 
Valium . . . . . . . . . . . . . . . . . . . . . . . . . . 755 .1 Lasix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,183 3.0 
Ionamin (phentermine), .,.,..... 730 ,1 Vitamin B-12. . . . . . . . . . . . . . . . . . . . . 1,723 2.4 
Hydrochlorothiazide ..,.,.,.,.. . . . . . . . . . 674 1.0 Dyazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1<723 2.4 
Tagamet . . . . . . . . . . . . . . . . . . . . . 654 1.0 Inderal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 593 2,2 
Phenergan expectorant with codeine . . 607 0,9 Aldomet . . . . . . . . . . . . . . . . . . . . . . . . . 1,261 1.7 
Erythromycin . . . . . . . . . . . . . . . . . 588 0.9 Dioxin . . . . . . . . . . . . . . . . . . . . . . . . . 1,168 1.6 
Reflex . . . . . . . . . . . . . . . . . . . . . . . 583 0.9 Motrgn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,059 1,4 
Thyroid . . . . . . . . . . . . . . . . . . . . . . 579 0.8 Diabinese . . . . . . . . . . . . . . . . . . . . . . . 972 1.3 
Fastin(phentermine) . . . . . . . . . . . . . . . . . . 532 0.8 Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 963 1.3 
Motnn. . ., ., ., . . . . . . . . . . . . . . 504 0.7 Hydrodiuril (hydrochlorothiazide). 919 1.3 
Amoxil(amoxicillin) . . . . . . . . . . . . . 488 0.7 Hygroton . . . . . . . . . . . . . . . . . . . . . . . . . . . 886 1.2 
Phenergan ...,,,,,.....,,.,.. 486 0.7 Tagamet . . . . . . . . . . . . . . . . . . . . . . . . . 790 1.1 
Inderal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 476 0.7 Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . 779 1.1 
Decadron . . . . . . . . . . . . . . . . . . . 468 0.7 Aldoril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 778 1.1 
Phentermina . . . . . . . . . . . . . . . . . . . . . . . . . . . 463 0.7 Valium . . . . . . . . . . . . . . . . . . . . . . . 772 1.1 
Tylenol with codeine . . . . . . . . . 448 0,7 Influenza virus vaccine, type A,8. 734 1.0 
Tylenol . . . . . . . . . . . . . . . . . . . . . . . . . 443 0.7 Nitroglycerin . . . . . . . . . . . . . . . . . . . 654 0.9 
rvocet-N, . . . . . . . . . . . . . . . . . . . . . . . . 438 0.6 Slow- K . . . . . . . . . . . . . . . . . . . . . . . . . . . 650 0.9 
I 
S.(erythromycin) . . . . . . . . . . . . . . . . . . . 434 0,6 Isordil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 639 0.9 
Actifed ., ., . . . . . . . . . . . . . . . . . . . . . . 482 1,6 
.rramycin . . . . . . . . . . . . . . . . . . . . . . . 428 0.6 Antivert . . . . . . . . . . . . . . . . . . . . . . . . . . 622 0.8 
Tranxene. ,, . . . . . . . . . . . . . . . . . . . . . . . . . 411 0.6 Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . 616 0.8 
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . 46,620 68.4 Clinoril . . . . . . . . . . . . . . . . . . . . . . 605 0,8 
See footnote st end of tsble. 
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Table 7. Number and percent distribution of drug mentions in ofhce visits to general and family practitioners by age of patient and most frequently named drugs 
United States, 1980—Con. 
Number of Number of 
Age of patient mentions Percent Age of patient mentions Percent _ 
and name of drugl in distribution and name of drug~ in distribution 
thousands thousands 
65 yeara and over—Con. 65 years and over—Con. 
Hydrochlorothiazide, .,.,.,.,., . . . . . . . . . 596 0.8 Lopressor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 469 0.6 
Penicillin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 542 0.7 Indocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 455 0.6 
Dalmane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 522 0.7 Darvocet-N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 449 0.6 
Orinaae, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501 0.7 Naprosyn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 440 0.6 
Nitro-bid (nitroglycerin). . . . . . . ., . . . ., ., ., 485 0.7 Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44,171 60.2 
1~a~ad on ~ha phy~i~i~n,~ entry on the Patient Record form. 
Table 8. Number and percent distribution of drug mentions in office visits to internists by most frequently named drugs: United States, 1980 
Number of 
Percent 
Name of drugl mentions 
distribution 
in thousands 
All drug mentions. , ., ., .,.,.,.,. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118,943 100.0 
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Table 9. Number and percent distribution of drug mentions in office visits to pediatricians by most frequently named drugs: United States, 1980 
Number of 
PercentName of drugl mentions 
@ in thousands distribution 
All drug mentions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72,825 100.0 
Poliomyelitis vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,829 6.6 
Diphtheria andtetanus toxoids and pertussis vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,564 6.3 
Tuberculin tine test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,409 4.7 
Anmxicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,146 4.3 
Allergy relief orshots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,991 4.1 
Penicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,252 3.1 
Dimetapp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,858 2.6 
Amoxil(amoxicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,538 2.1 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,527 2.1 
E.E.S.(etythromycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,440 2.0 
Aspirin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,236 1.7 
Dirnetane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,078 1.5 
Bicillin (penicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 977 1.3 
Phenergan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 892 1.2 
Lerotid (amoxicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 857 1.2 
Actifed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809 1.1 
Vaccination (undetermined) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795 1.1 
V-Cillin (penicillin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 794 1.1 
Novahistine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 789 1.1 
Erythromycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 753 1.0 
M-M-R (measles, mumps, rubella virus vaccine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735 1,0 
Diphtheria, tetanus toxoids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 735 1.0 
Tylenol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 1.0 
Phenergan expectorant with codeine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 656 0.9 
Rondec . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 654 0.9 
Septra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 632 0.9 
Vkemin B-12 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618 0.8 
Iosone(erythromycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 593 0.8 
riaminic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 591 0.8 
e Benadrvl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 575 0.8 
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29,799 40.9 
1&~ed on the physicians entry on the patient Record ‘em. 
Table 10. Number and percent distribution of drug mentions in office visits to obstetrician-gynecologists by most frequently named drugs United States, 1980 
Number of 
Name of drugl mentions Percent 
distributionin thousands 
All drug mentions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33,026 100.0 
Prenatel formula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,621 4.9 
Ortho-novum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,254 3.8 
Moniatat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,236 3.7 
Pmmarin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,215 3.7 
Matema . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,116 3.4 
Lofovral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 936 2.8 
Ampicillin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 780 2.4 
Wtimins (unspecified) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 729 2.2 
Stuartnatall+l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 680 2.1 
Flagyl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 649 2.0 
Tetracycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 587 1.8 
Ovral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 550 1.7 
Nateiins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521 1.6 
emulen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507 1.5 
o Sultrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506 1.5 
Norinyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459 1.4 
Residual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19,680 59.5 
1~a~ed on the phyaician,sentry on the patient R*ord form. 
14 achancedata 
Technical notes 
Source of data and sample design 
The information presented in this report is based on 
data collected by the National Center for Health 
Statistics through its National Ambulatory Medical 
Care Survey (NAMCS) during 1980. The target uni-
verse of NAMCS includes oftlce visits made within the 
coterrninous United States by ambulatory patients to 
nonfederally employed physicians who are principally 
engaged in office practice, but not in the specialties of 
anesthesiology, pathology, or radiology. Telephone 
contacts and nonoftlce visits’ are excluded. 
NAMCS utilizes a multistage probability sample 
design that involves samples of primary sampling units 
(PSU’S), physicians’ practices within PSU’S, and pa-
tient visits within physician practices. For 1980 a 
sample of 2,959 non-Federal, office-based physicians 
was selected from master files maintained by the 
American Medical Association and the American 
Osteopathic Association. The physician response rate 
for 1980 was 77.2 percent. Sampled physicians were 
asked to complete Patient Records (figure 1) for a sys-
tematic random sample of ofilce visits taking place 
during a randomly assigned weekly reporting period. 
During 1980, responding physicians completed 46,081 
Patient Records, on which they recorded 51,372 drug 
mentions. Characteristics of the physician’s practice, 
such as primary specialty and type of practice, were ob-
tained during an induction interview. The National 
Opinion Research Center, under contract to the National 
Center for Health Statistics, was responsible for the 
survey’s field operations. 
For a more detailed discussion of the limitations, 
qualifications, and definitions of the data collected in 
the NAMCS, see Vital and Health Statistics, Series 
13. No. 66.’2 
Estimates presented in this report differ from the 
estimates reported in the National Medical Care Utili-
zation and Expenditure Survey (NMCUES), another 
program of the National Center for Health Statistics 
(NCHS). The variation in estimates is due to differences 
in survey populations, data collection methodology, 
and definitions. The NMCUES, cosponsored by NCHS 
and the Health Care Financing Administration (HCFA), 
is a national panel survey of households in which 
information on visits to physicians’ ofilces and hospital 
outpatient departments was collected. Preliminary sur-
vey data as well as a discussion of the survey method-
ology are forthcoming from NCHS and HCFA. 
Sampling errors and rounding of numbers 
The standard error is primarily a measure of the 
sampling variability that occurs by chance because 
NOTE: A list of references follows the text. 
. 
only a sample, rather than the entire universe, is sur-
ve~ed. The-relative standard error of an estimate is ob-
tained by dividing the standard error by the estimate it-
self and is expressed as a percent of the estimate. 
Relative standard errors of selected aggregate visit sta-
tistics are shown in table L Standard errors for estimated 
percents of visits are shown in table II. Similar standard 
errors for drug statistics and percents are shown in ta-
bles III and IV. Tables I and II should be used to obtain 
the standard error of a specific drug mention (e.g., Dya-
zide). Tables III and IV should be used to obtain the 
standard error of a group of drug mentions (e.g., all drugs 
prescribed for hypertension). 
Estimates of office visits have been rounded to the 
nearest thousand. For this reason detailed figures 
within tables do not always add to totals. Rates and per-
cents were calculated on the basis of original, unrounded 
figures and will not necessarily agree precisely with 
percents calculated from rounded data. 
Definitions 
An ambulatoiypatient is an individual presenting 
himself for personal health services who is neithe 
bedridden nor currently admitted to any health c 
institution on the premises. * 
Aphysician eligiblefor NAikfCS is a duly licensed 
doctor of medicine (M.D.) or doctor of osteopathy 
(D. O.) currently in office-based practice who spends 
time in caring for ambulatory patients. Excluded from 
NAMCS are physicians who are hospital based; physi-
cians who specialize in anesthesiology, pathology, or 
radiology; physicians who are federally employed; phy-
sicians who treat only institutionalized patients; physi-
cians employed full time by an institution, and physicians 
who spend no time seeing ambulatory ,patients. 
An ojj$ce is a place that the physician identities as a 
Table 1. Approximate relative standard errora of ektimated number of office visits 
baaed on all physician specialties NAMCS, 1980 
Relative 
Estimated number of office visits standard 
in thousands error in 
Dercent 
5C43 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27.3 
1,000. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19.5 
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14.1 
5.000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9.4 
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7.3 
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.9 
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.9 
l 
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.5 
550,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.1 
Exsmp/eof use of rsb/e:An aggregata estimste of 75,000,000 visits hss a ralative standard 
error of 4.7 percent, or a standard emor of 3,525,000 viaita (4.7 percent of 75,000,000). 
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Table Il. Approximate standard errors of percents of estimated numbers of office visits based on all physician specialties NAMCS, 1980
l* Base of percent Estimated percent(number of office visits in thousands) 1 or99 i or95 100r90 20 or 80 30 or 70 50
Standard error in percent
500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 5.9 8.1 10.8 12.4 13.5
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.2 5.7 7.6 8.7 9.5
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.3 2.9 4.0 5.4 6.2 6.7
5,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.8 1.9 2.6 3.4 3.9 4.3
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1.8 2.4 2.8 3.0
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.4 0.9 1.3 1.7 2.0 2.1
50,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 0.8 1.1 1.2 1.3
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.2 0.4 0.6 0.8 0.9 ‘1.0
500,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0.3 0.4 0.4
Exampleof useof table: An estimate of30 percentbasedonan aggregateof 15,000,000viaits hasastandarderrorof2.4 percent, ora relativestandarderrorof8 percent[2.4 percent + 30
percent].
Table Ill. Approximate relative standard errors of estimated number of drug
mentions based on all physician specialties NAMCS, 1980
Relative
Estimated number of drug mentions standard
in thousands error in
percent
I,ooo............................................... 27.3
2,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . :9.7
5,m . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13.2
10,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
e
10.1
,ooo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8.2
,ooo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.8
Ico,ooo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6.2
3m,m . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.8
650,W . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.7
Examp/eof usa of table:An aggregate est!mate of 75,000,000 drug mentions has a ra!ative
standard error of 6.5 Dercent or a standard error of 4.875.OGU mentions [6.5 oercent of
75,CKKuxKr). ‘
. .
location for his ambulatory practice. Responsibility
over tnne for patient care and professional services ren-
dered there generalIy resides with the individual physi-
cian rather than an institution.
A visit is a direct personal exchange between an
ambulatory patient and a physician or a staff member
working under the physician’s supervision, for the pur-
pose of seeking care and rendering health services.
Adrugmention is the physician’s entry of apharma-
ceutical agent ordered or provided—by any route of
administration-for prevention, diagnosis, or treatment.
Generic as well as brand-name drugs are included, as
are nonprescription as well as prescription drugs. Along
with all new drugs, the physician also records continued
medications if the patient was specifically instructed
during the visit to continue the medication.
Table IV. Approximate standard errors of percents of estimated numbers of drug mentions based on all physician specialties: NAMCS, 1980
Base of percent
Estimated percent
(number of drug mentions in thousands)
? or99 5 or 95 100r90 20 or80 30 or 70 50
Standard error in percentage points
1,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.7 5.8 8.0 10.7 12.2 13.3
2)000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.9 4.1 5.7 7.6 8.7 9.4
5,000 . . . . . . . . . . . . . . . . . . . . ...<... . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.2 2.6 3.6 4.8 5.5 6.0
20,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.6 1.3 1.8 2.4 2.7 3.0
100,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.3 0.6 0.8 1.1 1.2 1.3
‘600,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.1 0.2 0.3 0.4 0.5 0.5
Example of use oftable:An estimate of 30 percent based on an aggregate of 12,500,000 drug mentions has a standard error of4.1 percent ora relative standard error of 13.7 percent (4.1
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